RNA m6A Methylation Regulators Multi-Omics Analysis in Prostate Cancer

Area of Science:

• Molecular Biology
• Oncology
• Epigenetics

Background:

• N6-methyladenosine (m6A) methylation is a prevalent RNA modification in animals.
• m6A regulators significantly influence RNA metabolism and are implicated in various cancers.
• Prostate cancer progression and treatment are areas where m6A regulators may play a critical role.

Purpose of the Study:

• To investigate the role of m6A regulators in prostate cancer.
• To analyze the expression patterns and prognostic significance of m6A regulators in prostate cancer datasets.
• To identify potential therapeutic targets based on m6A regulator expression.

Main Methods:

• Analysis of prostate cancer datasets from The Cancer Genome Atlas (TCGA).
• Examination of gene expression, DNA methylation status, and copy number variations (CNVs) of m6A regulators.
• Correlation analysis between m6A regulator expression and prostate cancer prognosis, including Gleason scores.
• In vitro experiments to assess the functional impact of specific m6A regulators.

Main Results:

• Significant differences in m6A regulator expression were observed between prostate cancer and normal tissues.
• m6A regulator expression varied notably across prostate cancers with different Gleason scores.
• CBLL1, FTO, YTHDC1, and HNRNPA2B1 were identified as crucial m6A regulators in prostate cancer.
• CBLL1 expression correlated with potential therapeutic agents, and HNRNPA2B1 knockdown inhibited cell migration and invasion.

Conclusions:

• m6A regulators are differentially expressed in prostate cancer and are associated with disease characteristics.
• Specific m6A regulators like CBLL1, FTO, YTHDC1, and HNRNPA2B1 are critical in prostate cancer.
• Targeting m6A regulators, such as CBLL1 and HNRNPA2B1, may offer novel therapeutic strategies for prostate cancer.